Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures subdued as investors weigh earnings, oil prices
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil prices hit fresh 6-week highs on renewed Middle East tensions
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Cytokinetics (CYTK) PT Lowered to $75 at BofA Securities
April 3, 2024 8:52 AM EDTBofA Securities analyst Jason Zemansky lowered the price target on Cytokinetics (NASDAQ: CYTK) to $75.00 (from $85.00) while maintaining a Neutral rating.
The analyst comments "Following our recent discussions with our KOL cardiologists who underscored 1) the near-term uncertainties over Cytokinetics competitive position and 2) the... More
